EP024/#463 Has hormone therapy any benefit on disease-free survival in ER-low positive/HER2-negative breast cancer?. (4th December 2022)

• Record Type: Journal Article
• Authors: Hamida, Karim Ben; Houcine, Yoldez; Hamza, Khedija; Maaoui, Amal; Kamoun, Salma; Hmidi, Amira; Ayadi, Senda; Chargui, Riadh; Driss, Maha
• Is Part Of: International journal of gynecological cancer. Volume 32(2022)Supplement 3
• Page Start: A59
• Page End: A59
• Publication Date: 2022-12-04
• Subjects: Generative organs, Female -- Cancer -- Periodicals; 616.99465
• DOI: 10.1136/ijgc-2022-igcs.115
• Languages: English
• ISSNs: 1048-891X

Abstract

Abstract : Objectives: We aimed to study the benefit in terms of survival of hormone therapy in patients with ER-low positive/HER2-negative breast cancer compared to patients with high ER-positive/HER2-negative breast cancer. Methods: Fifty patients diagnosed with ER-positive/HER2-negative breast cancer between January, 2015 and December, 2018 were identified. ER status was assessed using immunohistochemistry (IHC) based on American Society of Clinical Oncoloy/College of American Pathologists (ASCO/CAP) guidelines at the time of the study. According to the ER positivity by IHC, cases were categorized into two groups: ER-high positive if there was more than 10% of ER expression and ER-low positive if it ranged from 1 to 10%. Clinical and pathological data were collected from our institute database. Results: The median age in ER-positive patients was 57 years (range 35–80). Histological subtypes were as follows: no specific ductal type (n=45), lobular (n=2), mixed (n=1), and special ductal (n=). The median tumor SBR grade was II. The tumor stage was pT1 (eight cases), pT2 (17 cases), pT3 (12 cases), and pT4 (six cases) and not available in seven cases. Thirty-one patients were ER-high positive and 19 patients were ER-low positive. The median follow-up period was 20 months. All the patients received hormone therapy. In the ER-low positive group, five patients were free of relapse while 14 others presented a relapse (three local relapses and eleven distant relapses) among which seven patients died. Conclusions: Our study shows no survival benefit from hormone therapy in patients with ER-low positive breast cancer. Larger and prospective longitudinal studies are needed to validate the current ASCO/CAP.